Compare ESRT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | TBPH |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.4M | 824.9M |
| IPO Year | 2012 | 2013 |
| Metric | ESRT | TBPH |
|---|---|---|
| Price | $5.55 | $16.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.35 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 1.3M | 331.2K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | 0.25 | ★ 2.06 |
| Revenue | ★ $768,270,000.00 | $15,386,000.00 |
| Revenue This Year | $4.26 | $8.46 |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | $22.34 | ★ $8.14 |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.87 | $8.33 |
| 52 Week High | $8.76 | $21.03 |
| Indicator | ESRT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 56.35 |
| Support Level | $4.87 | $16.14 |
| Resistance Level | $6.70 | $17.24 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 57.84 | 55.66 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.